AM Biotech joins forces with PITDC to advance biotech innovation and expand into the trillion-dollar pharmaceutical market.

ambiotechadmin — Tue, 10 Sep 2024 02:03:14 +0000

With outstanding R&D achievements and impressive revenue performance, Ascension Medical Biotechnology (AM BioTech) has formed a partnership with the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) to launch multiple biotech projects and enter the trillion-dollar pharmaceutical market 3

Ascension Medical Biotechnology (AM BioTech), a leading domestic company specializing in exosome functional induction technology and a pioneer in exosome applications for beauty and hair growth, announced on August 30, 2024, its partnership with Medical and Pharmaceutical Industry Technology and Development Center (PITDC) through a “Pharmaceutical Project Cooperation Development Agreement.” This collaboration marks the official launch of several biotech and pharmaceutical development projects, as AM BioTech ventures into the trillion-dollar pharmaceutical market.

Leveraging its exclusive international patent for bio-pulsed technology, AM BioTech has applied this innovation to various medical and cosmetic research areas. The first commercial product utilizing this technology is ExoGiov, the world’s first exosome designed specifically for skin rejuvenation and hair growth. Unlike non-induced exosomes (Naive Exosomes), ExoGiov has achieved international recognition with an INCI certification in 2022. Its remarkable effectiveness, unique market position, and ease of use have led to significant revenue growth. The product, available in lyophilization powder, liquid, and skincare formulations, can be stored at room temperature, reflecting the company’s impressive performance within just three years of its establishment.

Dr. Richard Hsieh, Chairman of AM BioTech, stated that in addition to its applications in beauty and hair growth, the bio-pulsed technology is also being explored for potential pharmaceutical uses in obstetrics and gynecology, dentistry, ophthalmology, nephrology, orthopedics, otolaryngology, and major wound repair. Preclinical efficacy tests have been completed, and most animal trials are finalized, showing promising potential to address unmet medical needs in these fields. The company is actively positioning its international patents and will soon publish four international research papers.

Ensuring legal compliance and product development in both beauty and pharmaceutical sectors remains a core principle for AM BioTech. The company will adhere to international pharmaceutical regulations as it embarks on developing medical projects. The PITDC, renowned for its expertise in pharmaceutical development and regulatory affairs, will collaborate closely with AM BioTech. After extensive discussions and planning between both teams, the agreement will officially commence in September 2024. This partnership signifies a new milestone for AM BioTech as it enters the biotech pharmaceutical development arena.

Dr. Mu-Huan Su, Chairman of the PITDC, emphasized that the center’s mission is to assist domestic companies with pharmaceutical product development and guidance while facilitating communication among industry, government, academia, and research sectors. This approach aims to enhance the technical standards of the pharmaceutical industry, promote technological advancement, and achieve industry upgrading and internationalization. The PITDC and AM BioTech have been discussing this project for three years, focusing on pharmaceutical initiatives. Given Taiwan’s relatively small market, it can be challenging for local industries to invest in such R&D. However, AM BioTech’s commitment to substantial research in new indications and applications is highly commendable. This collaboration will not only upgrade but also internationalize Taiwan’s industry. We aim to accelerate AM Biotech’s key pharmaceutical ingredients, product development and launch by partnering with the PITDC research team. Our collaboration will address both domestic and international regulations, enhance quality management systems, and implement manufacturing technologies. This will reduce the risks of AM Biotech’s self-funded development, shorten time to market, and speed up integration into the international supply chain. The planned development will proceed in two stages, aiming to maximize the benefits of domestically produced high-value pharmaceutical products.

Dr. Richard Hsieh, Chairman of AM BioTech, concluded by expressing confidence that, with the combined efforts of both teams, preliminary results will soon be visible, and the commercialization of pharmaceutical products will follow. AM BioTech’s research achievements and patent strategy are well-planned, offering a competitive market advantage. With the PITDC’s support and the collaborative development plan, the launch of AM BioTech’s products in various pharmaceutical applications is anticipated to be imminent.

medical – AM Biotech

AM Biotech joins forces with PITDC to advance biotech innovation and expand into the trillion-dollar pharmaceutical market.

Read Moreread more

Join Us at 2026 New York Society of Cosmetic Chemists

Join Us at Cosmopack Asia 2025

Join Us at the 2025 Autumn International Beauty & Cosmetics Show